New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes

Medical Xpress - latest medical and health news stories · 1h ago

New data from a phase 2b study being presented at the 2026 annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), show that, for people living with obesity and type 2 diabetes, treatment with Eli Lilly's new investigational medication, EloraTZP, a combination of eloralintide and tirzepatide (TZP), resulted in weight loss of up to 23.3% at…

Read original article on Medical Xpress - latest medical and health news stories →

New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes

Related news